(Q33448647)

26 July 2017

A phase I/II study of 24 hour intravenous AZQ in recurrent primary brain tumors (English)

1 reference

26 July 2017

1 reference

Chamberlain MC

1

1 reference

26 July 2017

Prados MD

series ordinal

2

1 reference

26 July 2017

Silver P

series ordinal

3

1 reference

26 July 2017

Levin VA

series ordinal

4

1 reference

26 July 2017

1 December 1988

1 reference

Journal of Neuro-Oncology

26 July 2017

1 reference

26 July 2017

6

1 reference

26 July 2017

4

1 reference

26 July 2017

319-323

1 reference

https://scigraph.springernature.com/pub.10.1007/bf00177426

26 July 2017

0 references

cites work

Phase II and pharmacokinetic study of aziridinylbenzoquinone [2,5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone, diaziquone, NSC 182986] in high-grade gliomas.

1 reference

12 December 2020

Phase I trial of 5-day continuous infusion aziridinylbenzoquinone (AZQ, diazaquone, NSC 182968).

1 reference

12 December 2020

Chemotherapy and radiation therapy of human medulloblastoma in athymic nude mice.

1 reference

12 December 2020

Aziridinylbenzoquinone (AZQ) treatment of central nervous system leukemia

1 reference

12 December 2020

Comprehensive phase II evaluation of aziridinylbenzoquinone (AZQ, diaziquone) in recurrent human primary brain tumors

1 reference

12 December 2020

A phase I trial of aziridinylbenzoquinone (NSC 192986) in patients with previously treated acute leukemia

1 reference

12 December 2020

Phase I trial and pharmacokinetics of aziridinylbenzoquinone (NSC 182986) in humans

1 reference

12 December 2020

Combined modality treatment using radiation and/or chemotherapy in an athymic nude mouse-human medulloblastoma and glioblastoma xenograft model.

1 reference

12 December 2020

Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1

1 reference

12 December 2020

Phase II study of procarbazine, CCNU, and vincristine combination chemotherapy in the treatment of malignant brain tumors

1 reference

12 December 2020

Treatment of patients with recurrent primary brain tumors with AZQ.

1 reference

12 December 2020

2,5-Diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone I: Kinetics in aqueous solutions by high-performance liquid chromatography.

1 reference

12 December 2020

Biochemical activation of AZQ [3,6-diaziridinyl-2,5-bis(carboethoxyamino)-1,4-benzoquinone] to its free radical species

1 reference

12 December 2020

A phase II trial of 2,5,-diaziridinyl 3,6-bis (carboethoxy amino) 1,4-benzoquinone (AZQ, NSC 182986) in recurrent primary brain tumors

1 reference

12 December 2020

Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors

1 reference

12 December 2020

Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas.

1 reference

12 December 2020

Phase I-II evaluation of intra-arterial diaziquone for recurrent malignant astrocytomas.

1 reference

12 December 2020

Cellular pharmacology in murine and human leukemic cell lines of diaziquone (NSC 182986).

1 reference

12 December 2020

Potential central nervous system antitumor agents. Aziridinylbenzoquinones.

1 reference

12 December 2020

Phase I evaluation and pharmacokinetics of aziridinylbenzoquinone using a weekly intravenous schedule.

1 reference

12 December 2020

Brain tumor chemotherapy: an evaluation of agents in current use for phase II and III trials.

1 reference

12 December 2020

Phase I study of aziridinylbenzoquinone (NSC 182986).

1 reference

12 December 2020

Single-agent chemotherapy of brain tumors. A five-year review

1 reference

12 December 2020

PCNU treatment for recurrent malignant gliomas.

1 reference

12 December 2020

Aziridinylbenzoquinone in recurrent, progressive glioma of the central nervous system. A Phase II study by the Illinois Cancer Council.

1 reference

12 December 2020

Phase II study of aziridinylbenzoquinone in refractory lymphoma

1 reference

12 December 2020

Computed Tomography in the Evaluation of Malignant Glioma Before and After Therapy

1 reference

12 December 2020

Phase II study of aziridinylbenzoquinone (AZQ) in patients with central nervous system malignancies: a Southwest Oncology Group Study

1 reference

12 December 2020

Procarbazine hydrochloride in the treatment of brain tumors. Phase 2 study

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00177426

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference